Ralf L.
- Country
- Germany
- Department
- Praxis, Schwerpunkt gynäkologische Onkologie
Research Overview
- Phase III Randomized, Double-Blind Trial of Atezolizumab with Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients
- Adjuvant Dynamic Marker-Adjusted Personalized Therapy: Ribociclib Plus Endocrine Therapy Versus Chemotherapy in HR+/HER2- Early Breast Cancer
- Phase III Randomized Trial of Palbociclib Plus Endocrine Therapy Versus Endocrine Therapy Alone in HR+/HER2- Early Breast Cancer
Data & Insights
Has run more than one trial at 55 of 286 partner sites.
Specializations
Breast Cancer Research
This investigator specializes in the treatment of hormone receptor-positive (HR+) and HER2-negative breast cancer, with particular focus on early-stage disease management.
- Endocrine Therapy Optimization
- Early Breast Cancer Treatment
- Hormone Receptor-Positive Disease
The investigator explores therapeutic combinations to enhance treatment outcomes in early breast cancer.
Triple-Negative Breast Cancer
The investigator conducts research in triple-negative breast cancer treatment, focusing on innovative therapeutic approaches in the neoadjuvant and adjuvant settings.
- Neoadjuvant Chemotherapy
- Immunotherapy Integration
- Treatment Sequencing
Their work encompasses comprehensive treatment strategies for aggressive breast cancer subtypes.
Therapeutic Innovation
The investigator evaluates novel therapeutic combinations in breast cancer treatment, incorporating targeted therapies with standard treatment approaches.
- Targeted Therapy Development
- Treatment Optimization
- Clinical Outcomes Research
Research activities focus on improving survival outcomes through innovative treatment strategies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.